Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Osimertinib for the treatment of non-small cell lung cancer.

Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. Review.

PMID:
28116908
2.

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.

Soejima K, Yasuda H, Hirano T.

Expert Rev Clin Pharmacol. 2017 Jan;10(1):31-38. doi: 10.1080/17512433.2017.1265446. Epub 2016 Dec 2. Review.

PMID:
27885838
3.

Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.

Bollinger MK, Agnew AS, Mascara GP.

J Oncol Pharm Pract. 2018 Jul;24(5):379-388. doi: 10.1177/1078155217712401. Epub 2017 May 31. Review.

PMID:
28565936
4.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M.

Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.

PMID:
29290257
5.

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.

Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.

6.

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.

Koba T, Kijima T, Takimoto T, Hirata H, Naito Y, Hamaguchi M, Otsuka T, Kuroyama M, Nagatomo I, Takeda Y, Kida H, Kumanogoh A.

Medicine (Baltimore). 2017 Feb;96(6):e6087. doi: 10.1097/MD.0000000000006087.

7.

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Pirker R.

Curr Opin Oncol. 2016 Mar;28(2):115-21. doi: 10.1097/CCO.0000000000000260. Review.

PMID:
26720671
8.
9.

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

Tan CS, Cho BC, Soo RA.

Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Review.

PMID:
26898616
10.

Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.

Mariachiara M, Celeste R, Federico F, Nicole B, Antonio C.

Int Ophthalmol. 2018 Dec;38(6):2669-2675. doi: 10.1007/s10792-017-0749-2. Epub 2017 Oct 25.

PMID:
29071523
11.

Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.

Rossi A, Muscarella LA, Di Micco C, Carbonelli C, D'alessandro V, Notarangelo S, Palomba G, Sanpaolo G, Taurchini M, Graziano P, Maiello E.

Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1281-1288. doi: 10.1080/17425255.2017.1401064. Epub 2017 Nov 12. Review.

PMID:
29095090
12.

Osimertinib: First Global Approval.

Greig SL.

Drugs. 2016 Feb;76(2):263-73. doi: 10.1007/s40265-015-0533-4. Review.

PMID:
26729184
13.
14.

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Wang S, Cang S, Liu D.

J Hematol Oncol. 2016 Apr 12;9:34. doi: 10.1186/s13045-016-0268-z. Review.

15.

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Takeda M, Nakagawa K.

Int J Mol Sci. 2019 Jan 3;20(1). pii: E146. doi: 10.3390/ijms20010146. Review.

16.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D.

Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. Epub 2016 Jul 19.

17.

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.

Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A, Camargo AA.

Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.

PMID:
28625643
18.

Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.

Alsharedi M, Bukamur H, Elhamdani A.

Drugs Today (Barc). 2018 Jun;54(6):369-379. doi: 10.1358/dot.2018.54.6.2817668. Review.

PMID:
29998228
19.

Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Noda S, Kanda S.

Expert Rev Respir Med. 2016;10(5):547-56. doi: 10.1586/17476348.2016.1164603. Epub 2016 Mar 28. Review.

PMID:
26959310
20.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.

Ricciuti B, Chiari R, Chiarini P, Crinò L, Maiettini D, Ludovini V, Metro G.

Clin Drug Investig. 2016 Aug;36(8):683-6. doi: 10.1007/s40261-016-0411-1.

PMID:
27177916

Supplemental Content

Support Center